{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:49:45Z","timestamp":1789145385988,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clinthera.2019.12.007","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T08:57:03Z","timestamp":1579510623000},"page":"251-262.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib\u00a0+ Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR"],"prefix":"10.1016","volume":"42","author":[{"given":"Xiaohui","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.12.007_bib1","first-page":"74","article-title":"Global cancer statistics","volume":"55","author":"Parkin","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2019.12.007_bib2","article-title":"Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal","author":"Antunes","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clinthera.2019.12.007_bib3","first-page":"5","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2019.12.007_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2019.12.007_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clinthera.2019.12.007_bib6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.clinthera.2019.12.007_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.12.007_bib8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.12.007_bib11","author":"Genmab"},{"key":"10.1016\/j.clinthera.2019.12.007_bib12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Zhang","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.12.007_bib13","first-page":"29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States","volume":"24","author":"Carlson","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2019.12.007_bib14","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2019.12.007_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2019.12.007_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121353","article-title":"A\u00a0review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study","volume":"10","author":"Wan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2019.12.007_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2407-13-122","article-title":"Time-dependent endpoints as predictors of overall survival in multiple myeloma","volume":"13","author":"Felix","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2019.12.007_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","article-title":"Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States","volume":"10","author":"Jakubowiak","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clinthera.2019.12.007_bib19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","volume":"40","author":"van Agthoven","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2019.12.007_bib20","first-page":"1061","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2019.12.007_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","article-title":"Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales","volume":"14","author":"Brown","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2019.12.007_bib22","author":"Centers for Medicare & Medicaid Services"},{"issue":"3","key":"10.1016\/j.clinthera.2019.12.007_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","article-title":"Cost offsets in the treatment journeys of patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Ailawadhi","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.12.007_bib24","first-page":"243","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2019.12.007_bib25","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.12.007_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.12.007_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2019.12.007_bib28","first-page":"803","article-title":"Indirect comparisons and network meta-analyses","volume":"112","author":"Kiefer","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clinthera.2019.12.007_bib29","first-page":"1","article-title":"Network meta-analysis of antidepressants: a bridge too far?","volume":"5","author":"Eppel","year":"2019","journal-title":"J\u00a0Psychiat Ref"},{"key":"10.1016\/j.clinthera.2019.12.007_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2019.12.007_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","article-title":"An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.007_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year: in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2019.12.007_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2019.12.007_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:20Z","timestamp":1758963080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0149291819305910"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib\u00a0+ Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}